Drug
Vebreltinib clinical trials
Also written PLB1001, Bozitinib and APL-101.
- studies test it
- 20
- open now
- 11
- in phase 3
- 3
- first study started
- 2016
Keep track of what changes. Save the vebreltinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 13
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 9
Beijing Pearl Biotechnology Limited Liability Company (5) · Avistone Biotechnology Co., Ltd. (3) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Apollomics Inc. (2) · Washington University School of Medicine (1) · National Cancer Center, China (1) · Ceres Brain Therapeutics (1) · CHABiotech CO., Ltd (1)
Often tested with
Tested in the same studies.
Andamertinib (3) · Osimertinib (2) · Antineoplastic Agents (1) · Temozolomide (1) · Aflutinib (1)
Studies
Open first, then newest update. How each study uses vebreltinib is read from its arms, and is right about nine times in ten.
Testing it · 20
- Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingPhase 1/2Second Affiliated Hospital of Nanchang UniversityNCT07655622Written as Vebreltinib
- Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLCNot yet recruitingPhase 2Shanghai Chest HospitalNCT07549061Written as Vebreltinib
- Vebreltinib for Advanced or Metastatic CCSRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07153887Written as Vebreltinib
- Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung CancerNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07153770Written as Bozitinib
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)RecruitingPhase 3Beijing Pearl Biotechnology Limited Liability CompanyNCT05989542Written as PLB1001
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsRecruitingPhase 2Apollomics Inc.NCT03175224Written as APL-101 Oral Capsules
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingPhase 3Avistone Biotechnology Co., Ltd.NCT06970782Written as Vebreltinib
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingPhase 1/2Avistone Biotechnology Co., Ltd.NCT06343064Written as Vebreltinib
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06574347Written as Vebreltinib
- Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After SurgeryNot yet recruitingPhase 2Huashan HospitalNCT06780592Written as Vebreltinib + Temozolomide
- Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06644313Written as Vebreltinib
- A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)CompletedPhase 2Beijing Pearl Biotechnology Limited Liability CompanyNCT04258033Written as PLB1001
- Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male SubjectsCompletedPhase 1Ceres Brain TherapeuticsNCT07050316Written as CBT101
- A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).Active, not recruitingPhase 2/3Beijing Pearl Biotechnology Limited Liability CompanyNCT06105619Written as PLB1001
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 1/2Washington University School of MedicineNCT04743505Written as APL-101
- Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLCActive, not recruitingPhase 2National Cancer Center, ChinaNCT06827145Written as Vebreltinib
- Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid CancerCompletedPhase 1CHABiotech CO., LtdNCT04557306Written as CBT101 cells, every 2 weeks
- A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsStatus unknownPhase 1Apollomics Inc.NCT05367388Written as APL-101
- Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade GliomasCompletedPhase 1Beijing Pearl Biotechnology Limited Liability CompanyNCT02978261Written as PLB1001
- First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001CompletedPhase 1Beijing Pearl Biotechnology Limited Liability CompanyNCT02896231Written as PLB1001
Given in every arm · 1 — vebreltinib is usual care beside what is tested
Codes
What other systems call vebreltinib · ClinicalTrials.gg INT014545
- UNII (FDA) 2WZP8A9VFNVEBRELTINIBConfirmed FDA, Wikidata
- Wikidata Q125958237vebreltinibConfirmed FDA, Wikidata
- NCI Thesaurus C129717VebreltinibOne source FDA
- DrugBank DB16823One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2WZP8A9VFN | VEBRELTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q125958237 | vebreltinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C129717 | Vebreltinib | One source FDA |
| DrugBank | DB16823 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.